AX 194
Alternative Names: AX-194Latest Information Update: 26 Sep 2024
Price :
$50 *
At a glance
- Originator Artax Biopharma
- Class Small molecules
- Mechanism of Action Nck protein inhibitors; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 26 Sep 2024 Artax Biopharma plans a phase I trial in Autoimmune disorders (In volunteers) (PO) in 2026 (Artax Biopharma pipeline, September 2024)
- 01 Aug 2024 AX 194 is available for licensing as of 01 Aug 2024. https://artaxbiopharma.com/partners/ (Artax Biopharma website, August 2024)
- 01 Aug 2024 Preclinical trials in Autoimmune disorders in USA (PO), prior to August 2024 (Artax Biopharma pipeline, August 2024)